Drug Approval | February 10, 2025
NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
TFOS is indicated for the treatment of pulmonary arterial hypertension
TFOS is indicated for the treatment of pulmonary arterial hypertension
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Natco Pharma intends to defend the matter accordingly
The company will respond to the Warning Letter within the stipulated timelines
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Subscribe To Our Newsletter & Stay Updated
